Weight Management

Generic liraglutide injection is the first GLP-1 indicated for weight loss.

Orforglipron is an effective treatment, leading to significant body weight reduction and improved glycemic control.

GLP-1 receptor agonists like semaglutide show promise in reducing obesity-related cancer risks, while highlighting the need for ongoing safety monitoring.

A better understanding of the activation of amylin receptors is a step forward for developing new drugs.

The oral glucagon-like peptide agonist-1 met its primary end point and all secondary end points in a randomized, double-blind, placebo-controlled clinical trial for weight management.

Signos CGM empowers users to manage weight effectively through personalized insights and real-time glucose tracking.

Long-term obesity triggers aging biomarkers in young adults, linking excess weight to accelerated biological aging and chronic health risks.

FDA approves semaglutide for treating MASH, offering new hope for affected individuals.

New findings highlight environmental impacts on weight management.

Weight loss before IVF enhances pregnancy chances for women with obesity, potentially improving reproductive outcomes and fertility success rates.

Research reveals body fat percentage and waist circumference are more accurate predictors of mortality risk than BMI, highlighting flaws in traditional weight assessments.

New research reveals that GLP-1 receptor agonists like semaglutide may significantly reduce stroke impacts and improve recovery outcomes.

Insights from the American Diabetes Association 85th Scientific Sessions.

GLP-1 receptor agonists show promise in alleviating PCOS symptoms, including weight loss and menstrual regulation, despite needing further research.

GLP-1 anti-obesity medications enhance testosterone levels, aiding weight management and improving health outcomes for those with obesity and type 2 diabetes (T2D).

Long-term obesity accelerates aging in young adults, increasing risks for cardiovascular diseases and metabolic dysfunction.

GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.

Maridebart cafraglutide showed promising results for weight management in obesity and type 2 diabetes (T2D), achieving significant weight loss without plateau.

Real-world studies reveal GLP-1 medications like semaglutide and tirzepatide yield less weight loss than clinical trials, highlighting treatment discontinuation challenges.

GLP-1 medications like semaglutide face scrutiny over compounded versions, raising concerns about patient safety and counterfeit products in diabetes treatment.

A low-fat vegan diet reduces dietary acid load and promotes weight loss more effectively than a Mediterranean diet.

Low-energy total diet replacement programs show promise for individuals with obesity and type 2 diabetes, without increasing eating disorder risks.

Eli Lilly is expanding access to tirzepatide, a groundbreaking GLP-1 medication for weight management, offering more affordable options for obesity treatment.

Combining GLP-1 therapy with specific antibodies can reduce muscle loss during weight management, enhancing overall health outcomes.

By translating clinical evidence and real-world data into meaningful care, pharmacists uniquely position themselves to guide patients on GLP-1 therapies in obesity.

Although women might benefit from fattier breakfasts, men could respond best to carbohydrates.

Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk.

Katherine H. Saunders, MD, DABOM, explores the role of pharmacists in supporting long-term weight management with GLP-1 therapies, including strategies for counseling on lifestyle interventions, managing adverse effects, and ensuring patients receive individualized, evidence-based care.

Orforglipron showed promising results in managing type 2 diabetes, offering a potential oral alternative to injectable treatments.